RxDoctor Payments Data

Michael Till, MD

Family Medicine · Ponte Vedra Beach, FLNPI 1184665630

Payments from drug & device makers

$1,773in general payments, 2019–2025

Across 92 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$364
  • GSK$219
  • AstraZeneca$181
  • Pfizer$171
  • AbbVie$168
  • Merck$143
  • plus $527 from 13 others

What the payments were for

  • Food & beverage$1,773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,773 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$196,519
Medicare patients
391
Services billed
3,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$93,854
JardianceEmpagliflozin42$48,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$40,394
MounjaroTirzepatide33$37,749
XareltoRivaroxaban19$24,879
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$15,323
OzempicSemaglutide11$10,258
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,262
Atorvastatin Calcium540$4,754
Rosuvastatin Calcium264$3,332
Levothyroxine Sodium240$2,702
SynthroidLevothyroxine Sodium39$2,631
Metoprolol Succinate178$2,025
Omeprazole132$2,019
Pregabalin16$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$171$93,85466 claims
GSKTrelegy Ellipta$219$40,39438 claims
Lilly USA, LLCMounjaro$71$37,74933 claims
Novo NordiskOzempic$364$10,25811 claims
AstraZenecaBreztri Aerosphere$181$7,26211 claims
AbbVieSynthroid$168$2,63139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ponte Vedra Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →